Tap to start →
Photo: Vitaly Gariev / Unsplash
1 / 3
CagriSema is an investigational once-weekly injection from Novo Nordisk that combines cagrilintide, an amylin analog, with semaglutide in one pen.
2 / 3
CagriSema pairs two separate molecules: cagrilintide, which acts on amylin receptors, and semaglutide, the GLP-1 receptor agonist in Wegovy.
3 / 3
CagriSema could be the first amylin-plus-GLP-1 medicine for weight, so its FDA decision affects future treatment choices.
CagriSema is an investigational once-weekly injection from Novo Nordisk that combines cagrilintide, an amylin analog, with semaglutide in one pen.
Tap below for the full page. Not medical advice; talk to your clinician about your care.